Drug Profile
Icosabutate - NorthSea Therapeutics
Alternative Names: NST-4016; PRC-4016Latest Information Update: 28 Dec 2023
Price :
$50
*
At a glance
- Originator Pronova BioPharma
- Developer NorthSea Therapeutics; Pronova BioPharma
- Class Anti-inflammatories; Antifibrotics; Antihyperlipidaemics; Omega 3 fatty acids; Unsaturated fatty acids
- Mechanism of Action Cholesterol ester transfer protein inhibitors; FFAR1 protein agonists; GPR120 protein stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Dyslipidaemias; Hypertriglyceridaemia; Non-alcoholic steatohepatitis
- No development reported Hypercholesterolaemia
Most Recent Events
- 10 Nov 2023 Efficacy and adverse event data from phase IIb ICONA trial in Non-alcoholic steatohepatitis presented at the 74th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD-2023)
- 10 Nov 2023 NorthSea Therapeutics intends to pursue a registrational development path for icosabutate in Non-alcoholic steatohepatitis
- 10 Nov 2023 Updated efficacy, pharmacodynamics and adverse events data from the phase IIb ICONA trial in Non-alcoholic steatohepatitis released by NorthSea Therapeutics